

STIC-Biotech/ChemLib

From: Fredman, Jeffrey
Sent: Monday, January 07, 2002 3:25 PM
To: STIC-Biotech/ChemLib
Cc: Lacourciere, Karen
Subject: FW: Sequence search approval 09/975,123

I Approve.

Jeff Fredman

-----Original Message-----

From: Lacourciere, Karen
Sent: Monday, January 07, 2002 11:24 AM
To: Fredman, Jeffrey
Subject: Sequence search approval 09/975,123

Jeff-

Could you approve this sequence search? Each sequence is an antisense targeted to the same gene. Thank-you!
Karen

Please perform a sequence search in the commercial databases on the following sequences for 09/975,123. Please perform the search as a **length limited search, please limit the length of oligonucleotides to less than 100 nucleotides long:**

13-19, 21, 23-36, and 38-43

Thank-you!

Karen A. Lacourciere Ph.D.
CM1 11D09 GAU 1635
(703) 308-7523

Point of Contact:
Toby Port
Technical Info. Specialist
CM1-1E01 TEL: 308-3534
/2CH

mailbox 11E12

Searcher: _____	TYPE OF SEARCH:	VENDOR/COST(where applic.)
Phone: _____	NA Sequences: <u>28</u>	STN: _____
Location: _____	AA Sequences: _____	DIALOG: _____
	Structures: _____	Questel/Orbit: _____
		DBLink: _____
Online time: _____	Patent Family: _____	WWW-Internet: _____
	Other: _____	Other (specify): _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Author: JANE ZARA Title: 77512 Date: 8/12/03
 Accession: 1635 Refine Number: 6-5820 Serial Number: 09/975,123
 Media: 11003 Format: PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. 11Ej

Please enter a brief, but full, statement of the search topic and desired results, as narrow as the subject matter to be searched. Include the desired product, structures, keywords, synonyms, acronyms, and tag any numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Freier

Inventors: ASG ILGFBP5

Earliest Priority Filing Date: 10/9/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Seq ID #'s:
 15, 23, 24, 26-30
 33-36, 38-43.

For Interference + regular data base.
 — Limit ^{ALL} TO 100 NT's. ONLY.
 Thanks.

* These seq have been searched together before.

STAFF USE ONLY

Signature: [Signature]
 Date: 9/12/03
 Type of Search: Sequence #
 Refine Number: 6-5820
 Serial Number: 09/975,123
 Format: PAPER DISK E-MAIL

```

s00  Items  Description
s01  100  IGF1R IGF X R18
s02  11  S1 S2 ANTISENSE OR RIBOZYME?
s03  1  RD (unique items)
s04  14  S1 AND ANTISENSE OR RIBOZYME?
s05  1  RD (unique items)
s06  14  INSULIN (X) LIKE (X) GROWTH (X) FACTOR (X) BINDING (X) PRO-
    TEIN (X)
s07  11  S6 (S) ANTISENSE OR RIBOZYME?
s08  1  RD (unique items)
s09  42  S6 AND ANTISENSE OR RIBOZYME?
s10  17  RD (unique items)
***KWIC option is not available in file(s): 41, 42, 399

```

10/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5:BIOSIS Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

13216983 BIOSIS NO.: 200100424132

The IGF/IGFBP system in CNS malignancy.

AUTHOR: Zumkeller W(a); Westphal M

AUTHOR ADDRESS: (a)Department of Pediatrics, Martin-Luther-University
 Halle-Wittenberg, University Hospital, Ernst-Grube-Str. 40, 06097,
 Halle/Saale: walter.zumkeller@medizin.uni-halle.de**Germany

JOURNAL: Molecular Pathology 54 (4):p227-229 August, 2001

MEDIUM: print

ISSN: 1366-8714

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

...ABSTRACT: Both types of IGF receptor are expressed in gliomas and, in particular, the type I IGF receptor appears to be upregulated in malignant brain tissue. *Antisense* IGF-1 receptor mRNA induces an antitumour response, resulting in complete brain tumour regression. Clinical trials for the treatment of brain tumours in humans based on a gene transfer protocol using IGF-1 receptor *antisense* are under way. All six IGFBPs are expressed to a variable extent in brain tumours. High concentrations of IGFBP-2 are found in cerebrospinal fluid...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: *antisense* insulin-like growth factor-I receptor messenger RNA...

...*insulin*-*like* *growth* *factor* *binding* *protein*-*5*;

10/3,K/2 (Item 2 from file: 5)

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

13216984 BIOSIS NO.: 200100424133

Castration-induced up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.

AUTHOR: Miyake Hideaki; Pollak Michael; Sleave Martin E(a)

AUTHOR ADDRESS: (a)Division of Urology, University of British Columbia,
 2-2, 1133 Heather Street, Vancouver, BC, V6Z 3Z5**Canada

JOURNAL: Cancer Research 61 (11):p3000-3004 June 1, 2001

MEDIUM: print

Castration-induced up-regulation of *insulin*-*like* *growth* *factor*

***binding* *protein*--*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.**

ABSTRACT: Although *insulin*--*like* *growth* *factor* *binding* *protein*--*5* (IGFBP-5) has been shown to be implicated in prostate cancer progression, the functional role of IGFBP-5 in progression to androgen-independence remains largely...

...cells were stably transfected with IGFBP-5 gene, and IGFBP-5-overexpressing LNCaP tumors progressed significantly faster to androgen independence after castration compared with controls. *Antisense* mouse IGFBP-5 oligodeoxynucleotides (ODNs) were then designed that reduced IGFBP-5 expression in Shionogi tumor cells in vitro in a dose-dependent and sequence-specific manner. Growth of Shionogi tumor cells was inhibited by *antisense* IGFBP-5 ODN treatment in a time- and dose-dependent manner, which could be reversed by exogenous IGF-I. However, *antisense* IGFBP-5 ODN treatment had no additive inhibitory effect on Shionogi tumor cell growth when IGF-I activity was neutralized by anti-IGF-I antibody. *Antisense* IGFBP-5 ODN treatment resulted in decreased mitogen-activated protein kinase activity and number of cells in the S + G2-M phases of the cell cycle that directly correlated with reduced proliferation rate of Shionogi tumor cells. Systemic administration of *antisense* IGFBP-5 ODN in mice bearing Shionogi tumors after castration significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors...

...serves to enhance IGF bioactivity and raise the possibility that the response of prostate cancer to androgen withdrawal can be enhanced by strategies, such as *antisense* IGFBP-5 ODN therapy, that target IGF signal transduction.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*--*like* *growth* *factor* *binding* *protein*--*5*--...

...human IGFBP-5 gene {human *insulin*--*like* *growth* *factor* *binding* *protein*--*5* gene} (Hominidae)

10/3,K/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12099757 BIOSIS NO.: 199900394606

Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins.

AUTHOR: Rosen Florence; Pollak Michael(a)

AUTHOR ADDRESS: (a) Lady Davis Institute for Medical Research of the Jewish General Hospital, 3755 Cote Ste. Catherine**Canada

JOURNAL: International Journal of Oncology 15 (3):p589-594 Sept., 1999

ISSN: 1171-4608

KEYWORDS: IGF; Antisense

KEYWORDS: IGF; Antisense

LANGUAGE: English

SUMMARY LANGUAGE: English

...**ABSTRACT:** IGF-1 induced by IGF-1, IGF-1, and IGF-1 analogue with greatly reduced activity for IGF-1. Furthermore, we demonstrate that an *antisense* IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-1-stimulated tyrosine phosphorylation of IRS-1 and PI3K--induced IGF-1 stimulation. These data indicate...

KEYWORDS:

11842922 BIOSIS NO.: 199800189031

**Differential expression and localization of IGF-I and IGF binding proteins
in inflamed rat colon.**

AUTHOR: Seeh Jøerg E; Mahapatra Niru; Lund F Kay; Eysselein Viktor E;
McRoberts James A

AUTHOR ADDRESS: Harbor-UCLA Med. Cent., Div. Gastroenterol., Torrance, CA
**USA

JOURNAL: Journal of Receptor and Signal Transduction Research 18 (4-6):p
265-280 July-Nov., 1998

ISSN: 1079-8593

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: were sacrificed at 7 days after induction of colitis. Cryostat
sections of colon from TNB-treated and control rats were hybridized with
35 S-labeled *antisense* probes for IGF-1k, IGFBP-3, IGFBP-4 and IGFBP-5.
IGF-1 mRNA was up-regulated in lamina propria cells, submucosa and smooth
muscle...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor*
binding *protein*-*5*--

10/3,K/5 (Item 5 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

1142292 BIOSIS NO.: 199800209624

**Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5*
is independent of muscle cell differentiation, sensitive to rapamycin,
but insensitive to wortmannin and LY294002.**

AUTHOR: Rousse Sophie; Montarras Didier; Finset Christian; Dukcis Catherine
(a)

AUTHOR ADDRESS: (a) Inst. Natl. Sante Recherche Med., U.142, Hop. Saint
Antoine, 75571 Paris Cedex 12**France

JOURNAL: Endocrinology 139 (4):p1487-1493 April, 1998

ISSN: 0013-7227

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5*
is independent of muscle cell differentiation, sensitive to rapamycin,
but insensitive to wortmannin and LY294002.**

...ABSTRACT: and modulated by IGF binding proteins (IGFBPs) secreted by the
cells. The mouse C2 myoblast cell line stably transfected with a vector
expressing IGF-1 *antisense* RNA was used to show that specific IGFBP
expression changes with the state of the cells: high levels of IGFBP-1
expressed RNA RNA were...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor* *binding*
protein-*5*--

10/3,K/6 (Item 6 from file: 5)

DIALOG(R)File 6: Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

JOURNAL: Hormone Research Basel 4: 1991, 1: 1-4
CONFERENCE MEETING: 5th Joint Meeting of the European Society for
Paediatric Endocrinology and the Lawson Wilkins Society for Paediatric
Endocrinology, in Collaboration with the Australian Paediatric Endocrine
Group, the Japanese Society for Paediatric Endocrinology and the Latin
American Society for Paediatric Endocrinology, Stockholm, Sweden, June
22-26, 1990
ISSN: 0301-0163
RECORD TYPE: Citation
LANGUAGE: English

MISCELLANEOUS TERMS: ...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3
ANTISENSE OLIGONUCLEOTIDE...
...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 *ANTISENSE* OLIGONUCLEOTIDE
...

...*INSULIN*--*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5*;

10/3,K/7 (Item 7 from file: 5)
DIALOG(R)File 5:BIOSIS Previews,R1
(c) 2002 BIOSIS. All rts. reserv.

10733630 BIOSIS NO.: 199799321775
**A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in
the antiproliferative action of the antiestrogen ICI 182780.**
AUTHOR: Hlynh Hung(a); Yang Xiao-Peng; Pollak Michael
AUTHOR ADDRESS: (a)Dep. Med., McGill Univ., 3755 Cote Ste Catherine Rd.,
Montreal, PQ H3T 1E2**Canada
JOURNAL: Cell Growth & Differentiation 7 (11):p1501-1506 1996
ISSN: 1044-9523
RECORD TYPE: Abstract
LANGUAGE: English

**A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in
the antiproliferative action of the antiestrogen ICI 182780.**

...ABSTRACT: mRNA abundance, and increased IGFBP-5 protein accumulation in
the conditioned medium. Growth stimulation following estradiol exposure
was associated with opposite effects. An IGFBP-5 *antisense*
oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in
conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore,
this *antisense* oligodeoxynucleotide attenuated both
antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth
inhibition. These data demonstrate that estradiol down-regulates and ICI
up-regulates an...
MISCELLANEOUS TERMS: ...*INSULIN*--*LIKE* *GROWTH* *FACTOR* *BINDING*
PROTEIN *5*;*INSULIN*--*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*
5 mRNA

10/3,K/8 (Item 8 from file: 5)
DIALOG(R)File 5:BIOSIS Previews,R1
(c) 2002 BIOSIS. All rts. reserv.

10744570 BIOSIS NO.: 199800051771
**Osteogenic protein-1-mediated insulin-like growth factor gene expression in
primary cultures of rat osteoblastic cells.**
AUTHOR: Yeh Lee-Duan T (a); Aikawa Mariko I; Kitten Allison M; Olsen Merle S
; Lee John J
AUTHOR ADDRESS: (a)Dep. Cell Biol., Univ. Texas Health Sci. Cent., 7701 Fwy 360
Dallas, TX 75235

...ABSTRACT: a concentration-dependent manner. The IGFBP-4, -5, and -6 mRNA levels decreased dramatically in an IGF-1 concentration-dependent manner. In addition, coincubation of *antisense* oligonucleotides corresponding to IGF-1 or -II mRNA sequence with IGF-1 reduced the IGF-1-induced elevation in alkaline phosphatase activity. The present results...
MISCELLANEOUS TERMS: ...*INSULIN*-like* *GROWTH* *FACTOR*-binding*
PROTEIN-5*;

10/3,K/9 (Item 9 from file: 5)
DIALOG(R)File 1:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10381965 BIOSIS NO.: 199699004110

***Insulin*-like* *growth* *factor* *binding* *protein*-5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**

AUTHOR: James Payton L; Stewart Claire E H; Rotwein Peter
AUTHOR ADDRESS: Dep. Biochemistry Molecular Biophysics, 660 South Euclid Ave., Box 8231, St. Louis, MO 63110*USA
JOURNAL: Journal of Cell Biology 133 (3):p683-693 1996
ISSN: 0021-9525
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

***Insulin*-like* *growth* *factor* *binding* *protein*-5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**

...ABSTRACT: sense myoblasts show enhanced survival in low serum medium, remaining viable for at least four weeks in culture. By contrast, myoblasts expressing the IGFBP-5 *antisense* transcript differentiate prematurely and more extensively than control cells. The inhibition of myogenic differentiation by high level expression of IGFBP-5 could be overcome by...

10/3,K/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09533075 BIOSIS NO.: 199598049993

Localization of messenger ribonucleic acid for insulin-like growth factor-binding proteins in human skin by in situ hybridization.

AUTHOR: Batch J A(a); Mercuri F A; Edmondson S R; Werther G A
AUTHOR ADDRESS: (a)Cent. Hormone Res., Royal Children's Hosp., Flemington Rd., Parkville, 3052 VIC*Australia
JOURNAL: Journal of Clinical Endocrinology & Metabolism 79 (5):p1444-1449 1994
ISSN: 0893-2761
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: Insulin-like growth factor (IGF) binding proteins (IGFBPs) in human skin, we have used in situ hybridization to localize messenger ribonucleic acid (mRNA) for the six IGFBPs. *Antisense* and sense RNA probes for the IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6 sections of normal adult human skin were prepared...
MISCELLANEOUS TERMS: ...*INSULIN*-like* *GROWTH* *FACTOR*-binding*
PROTEIN-5*;

10/3, K/14 (Item 1 from file: 399)

Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries.

el-Aceily A; Chen X; Roberts V J; Shimasakai S; Ling N; LeRoith D; Roberts C T; Yen S S

Department of Reproductive Medicine, University of California School of Medicine, La Jolla 92035.

Journal of clinical endocrinology and metabolism (UNITED STATES) Jun 1994; 79: 1487-1496, ISSN 0021-472X Journal Code: 0375362

Abstract Grant No.: HL-4224-1; HL; NIDHD; HD-37613-11; HL; NICHD; HD-12503-10; HL; NICHD

Document type: Journal Article

Language: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... in specific cellular compartments of normal and PCOS human ovaries. Messenger ribonucleic acid (mRNA) was localized by in situ hybridization with specific 35S-labeled human *antisense* RNA probes, and protein was detected by immunohistochemistry using specific antisera. Thecal cells, but not granulosa cells (GC), of small antral follicles (3-6 mm...

...; Growth Factor II--analysis--AN; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*--*Like* *Growth*--*Factor*--*Binding*--*Protein* *5*; Insulin-Like-Growth Factor Binding Protein 6; Middle Age; Ovary--pathology--PA; Polycystic Ovary Syndrome--pathology--PA; RNA Probes; Receptor, IGF Type 1--analysis--AN...

...Chemical Name: Growth-Factor-Binding Protein 4; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*--*Like* *Growth*--*Factor*--*Binding*--*Protein* *5*; Insulin-Like-Growth-Factor-Binding Protein 6; RNA Probes; RNA, Messenger; Receptor, IGF Type 2; Insulin-Like Growth Factor 1; Insulin-Like Growth Factor II...

10/3, K/14 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Como Biotech Aps

PATENT: ECT International ; WO 99232953 A2 DATE: 20020425

APPLICATION NO: WO 99232953 A2 (19991023) *EP 1 311 111 (20001023) *US 10241840

CLASS: C12N 1/21; C12N 1/22; C12N 1/23; C12N 1/24; C12N 1/25; C12N 1/26; C12N 1/27; C12N 1/28; C12N 1/29; C12N 1/30; C12N 1/31; C12N 1/32; C12N 1/33; C12N 1/34; C12N 1/35; C12N 1/36; C12N 1/37; C12N 1/38; C12N 1/39; C12N 1/40; C12N 1/41; C12N 1/42; C12N 1/43; C12N 1/44; C12N 1/45; C12N 1/46; C12N 1/47; C12N 1/48; C12N 1/49; C12N 1/50; C12N 1/51; C12N 1/52; C12N 1/53; C12N 1/54; C12N 1/55; C12N 1/56; C12N 1/57; C12N 1/58; C12N 1/59; C12N 1/60; C12N 1/61; C12N 1/62; C12N 1/63; C12N 1/64; C12N 1/65; C12N 1/66; C12N 1/67; C12N 1/68; C12N 1/69; C12N 1/70; C12N 1/71; C12N 1/72; C12N 1/73; C12N 1/74; C12N 1/75; C12N 1/76; C12N 1/77; C12N 1/78; C12N 1/79; C12N 1/80; C12N 1/81; C12N 1/82; C12N 1/83; C12N 1/84; C12N 1/85; C12N 1/86; C12N 1/87; C12N 1/88; C12N 1/89; C12N 1/90; C12N 1/91; C12N 1/92; C12N 1/93; C12N 1/94; C12N 1/95; C12N 1/96; C12N 1/97; C12N 1/98; C12N 1/99; C12N 2/00; C12N 2/01; C12N 2/02; C12N 2/03; C12N 2/04; C12N 2/05; C12N 2/06; C12N 2/07; C12N 2/08; C12N 2/09; C12N 2/10; C12N 2/11; C12N 2/12; C12N 2/13; C12N 2/14; C12N 2/15; C12N 2/16; C12N 2/17; C12N 2/18; C12N 2/19; C12N 2/20; C12N 2/21; C12N 2/22; C12N 2/23; C12N 2/24; C12N 2/25; C12N 2/26; C12N 2/27; C12N 2/28; C12N 2/29; C12N 2/30; C12N 2/31; C12N 2/32; C12N 2/33; C12N 2/34; C12N 2/35; C12N 2/36; C12N 2/37; C12N 2/38; C12N 2/39; C12N 2/40; C12N 2/41; C12N 2/42; C12N 2/43; C12N 2/44; C12N 2/45; C12N 2/46; C12N 2/47; C12N 2/48; C12N 2/49; C12N 2/50; C12N 2/51; C12N 2/52; C12N 2/53; C12N 2/54; C12N 2/55; C12N 2/56; C12N 2/57; C12N 2/58; C12N 2/59; C12N 2/60; C12N 2/61; C12N 2/62; C12N 2/63; C12N 2/64; C12N 2/65; C12N 2/66; C12N 2/67; C12N 2/68; C12N 2/69; C12N 2/70; C12N 2/71; C12N 2/72; C12N 2/73; C12N 2/74; C12N 2/75; C12N 2/76; C12N 2/77; C12N 2/78; C12N 2/79; C12N 2/80; C12N 2/81; C12N 2/82; C12N 2/83; C12N 2/84; C12N 2/85; C12N 2/86; C12N 2/87; C12N 2/88; C12N 2/89; C12N 2/90; C12N 2/91; C12N 2/92; C12N 2/93; C12N 2/94; C12N 2/95; C12N 2/96; C12N 2/97; C12N 2/98; C12N 2/99; C12N 3/00; C12N 3/01; C12N 3/02; C12N 3/03; C12N 3/04; C12N 3/05; C12N 3/06; C12N 3/07; C12N 3/08; C12N 3/09; C12N 3/10; C12N 3/11; C12N 3/12; C12N 3/13; C12N 3/14; C12N 3/15; C12N 3/16; C12N 3/17; C12N 3/18; C12N 3/19; C12N 3/20; C12N 3/21; C12N 3/22; C12N 3/23; C12N 3/24; C12N 3/25; C12N 3/26; C12N 3/27; C12N 3/28; C12N 3/29; C12N 3/30; C12N 3/31; C12N 3/32; C12N 3/33; C12N 3/34; C12N 3/35; C12N 3/36; C12N 3/37; C12N 3/38; C12N 3/39; C12N 3/40; C12N 3/41; C12N 3/42; C12N 3/43; C12N 3/44; C12N 3/45; C12N 3/46; C12N 3/47; C12N 3/48; C12N 3/49; C12N 3/50; C12N 3/51; C12N 3/52; C12N 3/53; C12N 3/54; C12N 3/55; C12N 3/56; C12N 3/57; C12N 3/58; C12N 3/59; C12N 3/60; C12N 3/61; C12N 3/62; C12N 3/63; C12N 3/64; C12N 3/65; C12N 3/66; C12N 3/67; C12N 3/68; C12N 3/69; C12N 3/70; C12N 3/71; C12N 3/72; C12N 3/73; C12N 3/74; C12N 3/75; C12N 3/76; C12N 3/77; C12N 3/78; C12N 3/79; C12N 3/80; C12N 3/81; C12N 3/82; C12N 3/83; C12N 3/84; C12N 3/85; C12N 3/86; C12N 3/87; C12N 3/88; C12N 3/89; C12N 3/90; C12N 3/91; C12N 3/92; C12N 3/93; C12N 3/94; C12N 3/95; C12N 3/96; C12N 3/97; C12N 3/98; C12N 3/99; C12N 4/00; C12N 4/01; C12N 4/02; C12N 4/03; C12N 4/04; C12N 4/05; C12N 4/06; C12N 4/07; C12N 4/08; C12N 4/09; C12N 4/10; C12N 4/11; C12N 4/12; C12N 4/13; C12N 4/14; C12N 4/15; C12N 4/16; C12N 4/17; C12N 4/18; C12N 4/19; C12N 4/20; C12N 4/21; C12N 4/22; C12N 4/23; C12N 4/24; C12N 4/25; C12N 4/26; C12N 4/27; C12N 4/28; C12N 4/29; C12N 4/30; C12N 4/31; C12N 4/32; C12N 4/33; C12N 4/34; C12N 4/35; C12N 4/36; C12N 4/37; C12N 4/38; C12N 4/39; C12N 4/40; C12N 4/41; C12N 4/42; C12N 4/43; C12N 4/44; C12N 4/45; C12N 4/46; C12N 4/47; C12N 4/48; C12N 4/49; C12N 4/50; C12N 4/51; C12N 4/52; C12N 4/53; C12N 4/54; C12N 4/55; C12N 4/56; C12N 4/57; C12N 4/58; C12N 4/59; C12N 4/60; C12N 4/61; C12N 4/62; C12N 4/63; C12N 4/64; C12N 4/65; C12N 4/66; C12N 4/67; C12N 4/68; C12N 4/69; C12N 4/70; C12N 4/71; C12N 4/72; C12N 4/73; C12N 4/74; C12N 4/75; C12N 4/76; C12N 4/77; C12N 4/78; C12N 4/79; C12N 4/80; C12N 4/81; C12N 4/82; C12N 4/83; C12N 4/84; C12N 4/85; C12N 4/86; C12N 4/87; C12N 4/88; C12N 4/89; C12N 4/90; C12N 4/91; C12N 4/92; C12N 4/93; C12N 4/94; C12N 4/95; C12N 4/96; C12N 4/97; C12N 4/98; C12N 4/99; C12N 5/00; C12N 5/01; C12N 5/02; C12N 5/03; C12N 5/04; C12N 5/05; C12N 5/06; C12N 5/07; C12N 5/08; C12N 5/09; C12N 5/10; C12N 5/11; C12N 5/12; C12N 5/13; C12N 5/14; C12N 5/15; C12N 5/16; C12N 5/17; C12N 5/18; C12N 5/19; C12N 5/20; C12N 5/21; C12N 5/22; C12N 5/23; C12N 5/24; C12N 5/25; C12N 5/26; C12N 5/27; C12N 5/28; C12N 5/29; C12N 5/30; C12N 5/31; C12N 5/32; C12N 5/33; C12N 5/34; C12N 5/35; C12N 5/36; C12N 5/37; C12N 5/38; C12N 5/39; C12N 5/40; C12N 5/41; C12N 5/42; C12N 5/43; C12N 5/44; C12N 5/45; C12N 5/46; C12N 5/47; C12N 5/48; C12N 5/49; C12N 5/50; C12N 5/51; C12N 5/52; C12N 5/53; C12N 5/54; C12N 5/55; C12N 5/56; C12N 5/57; C12N 5/58; C12N 5/59; C12N 5/60; C12N 5/61; C12N 5/62; C12N 5/63; C12N 5/64; C12N 5/65; C12N 5/66; C12N 5/67; C12N 5/68; C12N 5/69; C12N 5/70; C12N 5/71; C12N 5/72; C12N 5/73; C12N 5/74; C12N 5/75; C12N 5/76; C12N 5/77; C12N 5/78; C12N 5/79; C12N 5/80; C12N 5/81; C12N 5/82; C12N 5/83; C12N 5/84; C12N 5/85; C12N 5/86; C12N 5/87; C12N 5/88; C12N 5/89; C12N 5/90; C12N 5/91; C12N 5/92; C12N 5/93; C12N 5/94; C12N 5/95; C12N 5/96; C12N 5/97; C12N 5/98; C12N 5/99; C12N 6/00; C12N 6/01; C12N 6/02; C12N 6/03; C12N 6/04; C12N 6/05; C12N 6/06; C12N 6/07; C12N 6/08; C12N 6/09; C12N 6/10; C12N 6/11; C12N 6/12; C12N 6/13; C12N 6/14; C12N 6/15; C12N 6/16; C12N 6/17; C12N 6/18; C12N 6/19; C12N 6/20; C12N 6/21; C12N 6/22; C12N 6/23; C12N 6/24; C12N 6/25; C12N 6/26; C12N 6/27; C12N 6/28; C12N 6/29; C12N 6/30; C12N 6/31; C12N 6/32; C12N 6/33; C12N 6/34; C12N 6/35; C12N 6/36; C12N 6/37; C12N 6/38; C12N 6/39; C12N 6/40; C12N 6/41; C12N 6/42; C12N 6/43; C12N 6/44; C12N 6/45; C12N 6/46; C12N 6/47; C12N 6/48; C12N 6/49; C12N 6/50; C12N 6/51; C12N 6/52; C12N 6/53; C12N 6/54; C12N 6/55; C12N 6/56; C12N 6/57; C12N 6/58; C12N 6/59; C12N 6/60; C12N 6/61; C12N 6/62; C12N 6/63; C12N 6/64; C12N 6/65; C12N 6/66; C12N 6/67; C12N 6/68; C12N 6/69; C12N 6/70; C12N 6/71; C12N 6/72; C12N 6/73; C12N 6/74; C12N 6/75; C12N 6/76; C12N 6/77; C12N 6/78; C12N 6/79; C12N 6/80; C12N 6/81; C12N 6/82; C12N 6/83; C12N 6/84; C12N 6/85; C12N 6/86; C12N 6/87; C12N 6/88; C12N 6/89; C12N 6/90; C12N 6/91; C12N 6/92; C12N 6/93; C12N 6/94; C12N 6/95; C12N 6/96; C12N 6/97; C12N 6/98; C12N 6/99; C12N 7/00; C12N 7/01; C12N 7/02; C12N 7/03; C12N 7/04; C12N 7/05; C12N 7/06; C12N 7/07; C12N 7/08; C12N 7/09; C12N 7/10; C12N 7/11; C12N 7/12; C12N 7/13; C12N 7/14; C12N 7/15; C12N 7/16; C12N 7/17; C12N 7/18; C12N 7/19; C12N 7/20; C12N 7/21; C12N 7/22; C12N 7/23; C12N 7/24; C12N 7/25; C12N 7/26; C12N 7/27; C12N 7/28; C12N 7/29; C12N 7/30; C12N 7/31; C12N 7/32; C12N 7/33; C12N 7/34; C12N 7/35; C12N 7/36; C12N 7/37; C12N 7/38; C12N 7/39; C12N 7/40; C12N 7/41; C12N 7/42; C12N 7/43; C12N 7/44; C12N 7/45; C12N 7/46; C12N 7/47; C12N 7/48; C12N 7/49; C12N 7/50; C12N 7/51; C12N 7/52; C12N 7/53; C12N 7/54; C12N 7/55; C12N 7/56; C12N 7/57; C12N 7/58; C12N 7/59; C12N 7/60; C12N 7/61; C12N 7/62; C12N 7/63; C12N 7/64; C12N 7/65; C12N 7/66; C12N 7/67; C12N 7/68; C12N 7/69; C12N 7/70; C12N 7/71; C12N 7/72; C12N 7/73; C12N 7/74; C12N 7/75; C12N 7/76; C12N 7/77; C12N 7/78; C12N 7/79; C12N 7/80; C12N 7/81; C12N 7/82; C12N 7/83; C12N 7/84; C12N 7/85; C12N 7/86; C12N 7/87; C12N 7/88; C12N 7/89; C12N 7/90; C12N 7/91; C12N 7/92; C12N 7/93; C12N 7/94; C12N 7/95; C12N 7/96; C12N 7/97; C12N 7/98; C12N 7/99; C12N 8/00; C12N 8/01; C12N 8/02; C12N 8/03; C12N 8/04; C12N 8/05; C12N 8/06; C12N 8/07; C12N 8/08; C12N 8/09; C12N 8/10; C12N 8/11; C12N 8/12; C12N 8/13; C12N 8/14; C12N 8/15; C12N 8/16; C12N 8/17; C12N 8/18; C12N 8/19; C12N 8/20; C12N 8/21; C12N 8/22; C12N 8/23; C12N 8/24; C12N 8/25; C12N 8/26; C12N 8/27; C12N 8/28; C12N 8/29; C12N 8/30; C12N 8/31; C12N 8/32; C12N 8/33; C12N 8/34; C12N 8/35; C12N 8/36; C12N 8/37; C12N 8/38; C12N 8/39; C12N 8/40; C12N 8/41; C12N 8/42; C12N 8/43; C12N 8/44; C12N 8/45; C12N 8/46; C12N 8/47; C12N 8/48; C12N 8/49; C12N 8/50; C12N 8/51; C12N 8/52; C12N 8/53; C12N 8/54; C12N 8/55; C12N 8/56; C12N 8/57; C12N 8/58; C12N 8/59; C12N 8/60; C12N 8/61; C12N 8/62; C12N 8/63; C12N 8/64; C12N 8/65; C12N 8/66; C12N 8/67; C12N 8/68; C12N 8/69; C12N 8/70; C12N 8/71; C12N 8/72; C12N 8/73; C12N 8/74; C12N 8/75; C12N 8/76; C12N 8/77; C12N 8/78; C12N 8/79; C12N 8/80; C12N 8/81; C12N 8/82; C12N 8/83; C12N 8/84; C12N 8/85; C12N 8/86; C12N 8/87; C12N 8/88; C12N 8/89; C12N 8/90; C12N 8/91; C12N 8/92; C12N 8/93; C12N 8/94; C12N 8/95; C12N 8/96; C12N 8/97; C12N 8/98; C12N 8/99; C12N 9/00; C12N 9/01; C12N 9/02; C12N 9/03; C12N 9/04; C12N 9/05; C12N 9/06; C12N 9/07; C12N 9/08; C12N 9/09; C12N 9/10; C12N 9/11; C12N 9/12; C12N 9/13; C12N 9/14; C12N 9/15; C12N 9/16; C12N 9/17; C12N 9/18; C12N 9/19; C12N 9/20; C12N 9/21; C12N 9/22; C12N 9/23; C12N 9/24; C12N 9/25; C12N 9/26; C12N 9/27; C12N 9/28; C12N 9/29; C12N 9/30; C12N 9/31; C12N 9/32; C12N 9/33; C12N 9/34; C12N 9/35; C12N 9/36; C12N 9/37; C12N 9/38; C12N 9/39; C12N 9/40; C12N 9/41; C12N 9/42; C12N 9/43; C12N 9/44; C12N 9/45; C12N 9/46; C12N 9/47; C12N 9/48; C12N 9/49; C12N 9/50; C12N 9/51; C12N 9/52; C12N 9/53; C12N 9/54; C12N 9/55; C12N 9/56; C12N 9/57; C12N 9/58; C12N 9/59; C12N 9/60; C12N 9/61; C12N 9/62; C12N 9/63; C12N 9/64; C12N 9/65; C12N 9/66; C12N 9/67; C12N 9/68; C12N 9/69; C12N 9/70; C12N 9/71; C12N 9/72; C12N 9/73; C12N 9/74; C12N 9/75; C12N 9/76; C12N 9/77; C12N 9/78; C12N 9/79; C12N 9/80; C12N 9/81; C12N 9/82; C12N 9/83; C12N 9/84; C12N 9/85; C12N 9/86; C12N 9/87; C12N 9/88; C12N 9/89; C12N 9/90; C12N 9/91; C12N 9/92; C12N 9/93; C12N 9/94; C12N 9/95; C12N 9/96; C12N 9/97; C12N 9/98; C12N 9/99; C12N 10/00; C12N 10/01; C12N 10/02; C12N 10/03; C12N 10/04; C12N 10/05; C12N 10/06; C12N 10/07; C12N 10/08; C12N 10/09; C12N 10/10; C12N 10/11; C12N 10/12; C12N 10/13; C12N 10/14; C12N 10/15; C12N 10/16; C12N 10/17; C12N 10/18; C12N 10/19; C12N 10/20; C12N 10/21; C12N 10/22; C12N 10/23; C12N 10/24; C12N 10/25; C12N 10/26; C12N 10/27; C12N 10/28; C12N 10/29; C12N 10/30; C12N 10/31; C12N 10/32; C12N 10/33; C12N 10/34; C12N 10/35; C12N 10/36; C12N 10/37; C12N 10/38; C12N 10/39; C12N 10/40; C12N 10/41; C12N 10/42; C12N 10/43; C12N 10/44; C12N 10/45; C12N 10/46; C12N 10/47; C12N 10/48; C12N 10/49; C12N 10/50; C12N 10/51; C12N 10/52; C12N 10/53; C12N 10/54; C12N 10/55; C12N 10/56; C12N 10/57; C12N 10/58; C12N 10/59; C12N 10/60; C12N 10/61; C12N 10/62; C12N 10/63; C12N 10/64; C12N 10/65; C12N 10/66; C12N 10/67; C12N 10/68; C12N 10/69; C12N 10/70; C12N 10/71; C12N 10/72; C12N 10/73; C12N 10/74; C12N 10/75; C12N 10/76; C12N 10/77; C12N 10/78; C12N 10/79; C12N 10/80; C12N 10/81; C12N 10/82; C12N 10/83; C12N 10/84; C12N 10/85; C12N 10/86; C12N 10/87; C12N 10/88; C12N 10/89; C12N 10/90; C12N 10/91; C12N 10/92; C12N 10/93; C12N 10/94; C12N 10/95; C12N 10/96; C12N 10/97; C12N 10/98; C12N 10/99; C12N 11/00; C12N 11/01; C12N 11/02; C12N 11/03; C12N 11/04; C12N 11/05; C12N 11/06; C12N 11/07; C12N 11/08; C12N 11/09; C12N 11/10; C12N 11/11; C12N 11/12; C12N 11/13; C12N 11/14; C12N 11/15; C12N 11/16; C12N 11/17; C12N 11/18; C12N 11/19; C12N 11/20; C12N 11/21; C12N 11/22; C12N 11/23; C12N 11/24; C12N 11/25; C12N 11/26; C12N 11/27; C12N 11/28; C12N 11/29; C12N 11/30; C12N 11/31; C12N 11/32; C12N 11/33; C12N 11/34; C12N 11/35; C12N 11/36; C12N 11/37; C12N 11/38; C12N 11/39; C12N 11/40; C12N 11/41; C12N 11/42; C12N 11/43; C12N 11/44; C12N 11/45; C12N 11/46; C12N 11/47; C12N 11/48; C12N 11/49; C12N 11/50; C12N 11/51; C12N 11/52; C12N 11/53; C12N 11/54; C12N 11/55; C12N 11/56; C12N 11/57; C12N 11/58; C12N 11/59; C12N 11/60; C12N 11/61; C12N 11/62; C12N 11/63; C12N 11/64; C12N 11/65; C12N 11/66; C12N 11/67; C12N 11/68; C12N 11/69; C12N 11/70; C12N 11/71; C12N 11/72; C12N 11/73; C12N 11/74; C12N 11/75; C12N 11/76; C12N 11/77; C12N 11/78; C12N 11/79; C12N 11/80

Use of antisense nucleic acids/analogs inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders

INVENTOR/AUTHOR : Weir, George Arthur; Wright, Christopher John
LOCATION: Australia
ASSIGNEE: Royal Children's Hospital Research Foundation
PATENT: PCT International ; WO 94/036 A1 DATE: 960125
APPLICATION: WO 94/041 A1 DATE: 940715 (940715)
PAGES: 111 pp. NOEN: 111112 LANGUAGE: English CLASS: A61K-031/70A;
A61K-12/12B; A61K-12/12B DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR;
BY; CA; CH; CN; CO; DE; DK; EE; ES; FI; GB; GR; HU; IS; JP; KE; KG; KP; KR;
KB; KK; LR; LT; LU; LV; MD; ME; MN; MX; MY; NO; NZ; PL; PT; RO; RU; SD; SE;
SG; SI; SK; TJ; TM; TT DESIGNATED REGIONAL: KE; MW; SD; SZ; SG; AT; BE; CH;
DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
CM; GA; GN; ML; MR; NE; SN; TD; TG

10/3,K/16 (Item 1 from file: 35)

DIALOG(R)File 16: Dissertation Abstracts Online
(c) 2002 ProQuest Info&Learning. All rts. reserv.

01439558 ORDER NO: AADAA-19533739

***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS
MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**

Author: JAMES, PAYTON LEIGH

Degree: Ph.D.

Year: 1995

Corporate Source/Institution: WASHINGTON UNIVERSITY (0252)

Source: VOLUME 56/06-B OF DISSERTATION ABSTRACTS INTERNATIONAL.

PAGE 2987. 158 PAGES

***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS
MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**

...dependent manner.

Stable transfectants of the C2 cell line were established which constitutively express the coding sequence of IGFBP-5 in either the sense or *antisense* orientation to determine the function of this protein during myogenic differentiation. Forced expression of the *antisense* transcripts caused rapid differentiation as assessed by myotube formation, creatine kinase activity, and the production of myosin heavy chain and the muscle-specific transcription factor...

10/3,K/17 (Item 1 from file: 159)

DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog Corporation. All rts. reserv.

02322558 PMID: 97604744

Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5* (IGFBP-5) (Meeting abstract).

Hynd; Elin; et al ; 1998

Lady Davis Research Inst., Kentville, Nova Scotia, Canada

Proc Ann Meet Am Assoc Cancer Res, 1998, 39, 1100-1100

Document Type: MEETING ABSTRACT

Language: ENGLISH

Main Citation Owner: NATHAN

Record type: Completed

Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5*

and anti-estrogen-induced growth inhibition. These results indicate that 101
102 increases cell growth by binding to ER.

Chemical Name: 101-102; Estradiol; Estrogen Antagonists; Insulin-
like Growth Factor-binding Protein-5; RNA, Messenger

5/3,K/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Tor;

LOCATION: Den.

ASSIGNEE: Cml Biotech Aps

PATENT: PCT International ; WO 200201953 A2 DATE: 20020426

APPLICATION: WO 200100695 (20011019) *DK 20001571 (20001020) *US PV241840 (20001020)

PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/435A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GB; GD; GE; GR; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; ME; MK; MN; MW; MX; MY; NZ; OM; PA; PE; PG; PH; PK; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; SM; SN; SR; ST; SV; TC; TD; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; EG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; NG; SN; TD; TG

5/3,K/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134125934 CA: 134(10)125934z PATENT

IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors

INVENTOR(AUTHOR): Gleave, Martin

LOCATION: Can.,

ASSIGNEE: The University of British Columbia; Miyake, Hideaki

PATENT: PCT International ; WO 200105435 A2 DATE: 20010125

APPLICATION: WO 2000CA853 (20000719) *US PV144495 (19990719)

PAGES: 45 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GR; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; ME; MK; MN; MW; MX; MY; NZ; OM; PA; PE; PG; PH; PK; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; EG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; NG; SN; TD; TG

...ABSTRACT: and immediately 100 binding proteins (LFBPs) secreted by the cells. The use of myristoyl cell line stably transfected with a vector producing LFBP-12 (myristoyl-LFBP-12) was used to show that specific LFBP-12 expression coincided with the release of the soluble form of LFBP-12.

3/3,K/3 (Item 1 from file: 399)

CHALICE R. P. L. AMERICA SPANISH R

ALL AMERICAN CHEMICAL COMPANY. All rights reserved.

134125934 CA: 134(10)125934z PATENT

IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors

INVENTOR AUTHOR : Blom, Martin

LOCATION: N.Y.

ASSIGNOR: The University of British Columbia; Miyake, Hideaki

PATENT: PCT International ; W. 1991.149. AL. DATE: 21.11.93

APPLICATION: WO 91/004495 (1991.01.19)

PAGES: 48 pp. CODEN: PXXXX. LANGUAGE: English CLASS: A61K-048/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DO; EE; ES; FI; GB; GR; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; NE; NL; NO; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TR; TT; UA; UG; US; VE; VN; YU; ZA; ZW; AM; AG; BY; KG; KZ; MD; RU; TC; TM. DESIGNATED REF. N. NAL: GR; HU; KE; LS; MW; ND; SI; SL; SZ; TD; TG; TW; AT; BE; CH; CY; DE; DK; EE; FI; FR; GE; GR; IE; IT; LU; MC; NL; PT; SE; BF; BG; BR; CC; CI; CM; CA; CN; GW; ML; MK; NE; SN; TD; TG

File 0:Selected Exhibits (Research)
File 1:Biological Abstracts
File 2:Biochem Previews R 1970-2002/Aug W1
File 3:BIOSIS
File 6:BNIP 1984-2002/Aug W2
File 7:2002 BIOS, Intl Copyright All Rights Res
File 8:Cell Abstr(R) 1970-2002/Aug W1
File 9:Cell Engineering Info. Inc.
File 34:SciSearch Cited Ref Sci 1974-2002/Aug W3
File 35:Inst for Sci Info
File 66:Instl Conferences 1993-2002/Aug W1
File 71:ELSEVIER ELSEVIER 1994-2002/Aug W1
File 72:Elsevier Science B.V.
File 73:EMBASE 1974-2002/Aug W2
File 74:2002 Elsevier Science B.V.
File 76:Life Sciences Collection 1982-2002/Jul
File 77:Life Cambridge Sci Abs
File 94:INST-BPlus 1985-2002/Jun W3
File 95:2002 Japan Science and Tech Corp(JST)
File 98:General Sci Abs/Full-Text 1984-2002/Jun
File 99:The HW Wilson Co.
File 99:Wilson Appl. Sci. & Tech Abs 1983-2002/Jun
File 100:The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2002/Aug W1
File 136:NewsRx
File 143:Biol. & Agric. Index 1983-2002/Jun
File 144:The HW Wilson Co
File 144:Pascal 1973-2002/Aug W2
File 145:2002 INIST-CNRS
File 155:MEDLINE(R) 1966-2002/Aug W2
File 172:EMBASE Alert 2002/Aug W2
File 173:2002 Elsevier Science B.V.
File 266:FIDRIP 2002/Jun
File 267:Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotech Abs 1970-2002/Jun
File 316:2002 DECHEMA
File 357:Derwent Biotech Res. 1982-2002/June W1
File 358:Thomson Derwent & ISI
File 358:Current BioTech Abs 1983-2001/Oct
File 359:2001 DECHEMA
File 369:New Scientist 1994-2002/Jul W2
File 370:Reed Business Information Ltd.
File 370:Science 1976-1999/Jul W3
File 371:1999 AAAS
File 399:CA SEARCH(R) 1967-2002/UD=13787
File 400:2002 AMERICAN CHEMICAL SOCIETY
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
File 435:Inst for Sci Info
File 436:Environ. Eng. 1984-2002/Aug W1
File 437:Environ. Eng. 1984-2002/Aug W1
File 438:Environ. Eng. 1984-2002/Aug W1
File 439:Environ. Eng. 1984-2002/Aug W1
File 440:Environ. Eng. 1984-2002/Aug W1
File 441:Environ. Eng. 1984-2002/Aug W1
File 442:Environ. Eng. 1984-2002/Aug W1
File 443:Environ. Eng. 1984-2002/Aug W1
File 444:Environ. Eng. 1984-2002/Aug W1
File 445:Environ. Eng. 1984-2002/Aug W1
File 446:Environ. Eng. 1984-2002/Aug W1
File 447:Environ. Eng. 1984-2002/Aug W1
File 448:Environ. Eng. 1984-2002/Aug W1
File 449:Environ. Eng. 1984-2002/Aug W1
File 450:Environ. Eng. 1984-2002/Aug W1

DEPT. OF THE ARMY, WASHINGTON, D. C., 1949. 149

© 2002 BIOSIS. All rts. reserv.

growth factor II with high binding affinity. Modulates muscle differentiation through an insulin like growth factor-dependent mechanism.

James, Payton L.
Stewart, Claire E. B; Reitwein, Peter
The Journal of Cell Biology / Cell Biol. v. 133 no. 1 May 1996 p. 683-93
SPECIAL FEATURES: 1111 11 ISSN: 0021-9525
LANGUAGE: English
COUNTRY OF PUBLICATION: United States

ABSTRACT: The function of insulin-like growth factor binding protein-5 (IGFBP-5) in myogenesis, a process stimulated by IGFs, was studied using C2 myoblasts. Compared with vector-transfected control cells, C2 myoblasts expressing an IGFBP...

...extracellular matrix during proliferation and subsequently did not differentiate normally. In contrast, differentiation was premature and more extensive in the presence of an IGFBP-5 antisense transcript. The inhibitory effects of high IGFBP-5 expression were overcome by exogenous IGFs. These findings are in agreement with a model in which IGFBP...

8/3,K/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Como Biotech Aps

PATENT: PCT International ; WO 200232953 A2 DATE: 20020425

APPLICATION: WO 2001DK695 (20011019) *DK 20031571 (20031020) *US PV241840 (20031020)

PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/435A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; EC; EE; EG; ES; FI; FR; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3,K/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

124270541 CA: 124(20)270541s PATENT

Use of antisense nucleic acids/analogues inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders

INVENTOR(AUTHOR): Reiter, Peter; Reiter, Peter; Reiter, Peter; Reiter, Peter

LOCATION: Australia

ASSIGNEE: Reiter, Peter; Reiter, Peter; Reiter, Peter; Reiter, Peter

PATENT: PCT International ; WO 200232953 A2 DATE: 20020425

APPLICATION: WO 2001DK695 (20011019) *DK 20031571 (20031020) *US PV241840 (20031020)

PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-001/70A;

C07K-014/435A; C07K-014/435A DESIGNATED COUNTRIES: AM; AT; AU; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; EC; EE; EG; ES; FI; FR; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG